Scotland’s New Cancer Frontier: From Personalised Vaccines in Edinburgh to AI-Powered Diagnosis
How researchers, NHS clinicians and life-sciences companies are reshaping the search for earlier diagnosis and more individualised cancer treatment
Scotland’s changing cancer landscape
Scotland is entering a new phase in cancer research, with advances in personalised treatment, artificial intelligence and early diagnosis increasingly moving from university laboratories into clinical testing.
The need is substantial. Public Health Scotland recorded 37,657 new cancer registrations in 2024, while cancer remained responsible for 16,352 deaths. At the same time, the age-standardised risk of dying from cancer has fallen over the past decade, underlining both the progress already made and the scale of the challenge that remains.
Against that background, Edinburgh, Glasgow and other Scottish research centres are becoming important parts of a wider effort to change how cancer is detected, treated and monitored.
Personalised vaccines reach Edinburgh
One of the most striking developments is taking place in a field that, only a few years ago, was largely experimental: personalised cancer vaccines.
In August 2026, researchers at the University of Edinburgh said patients at the Western General Hospital had contributed to an international Phase 3 trial of an individualised cancer vaccine for people with high-risk melanoma following surgery. The Edinburgh site formed part of the wider INTerpath-001 study, which reported positive results for recurrence-free and distant metastasis-free survival when the investigational therapy was combined with pembrolizumab.
The vaccine is designed according to mutations found in each patient’s tumour, with the aim of training the immune system to recognise and attack cancer cells more precisely.
For Edinburgh, the development is significant not because a new treatment has already become standard care, but because Scottish patients and research teams have been involved in one of the most advanced clinical investigations of an individualised cancer vaccine to date. Further analysis and regulatory review are still required before its place in routine treatment can be determined.
The wider lesson is that cancer therapy is increasingly being designed around the molecular characteristics of a patient’s disease rather than relying solely on a one-size-fits-all approach.
AI enters the screening room
Personalised medicine is only one part of Scotland’s research story. Another is artificial intelligence.
A prospective breast-screening study involving 10,889 women in NHS Grampian examined different ways of integrating an AI tool into the mammography pathway. Published in Nature Cancer in March 2026, the GEMINI study found that one workflow could increase cancer detection by 10.4 per cent while maintaining the recall rate and reducing clinician workload by up to 31 per cent.
The findings are encouraging, but they also illustrate why clinical implementation cannot be based on algorithms alone. The study evaluated different workflows, and the research emphasised that AI should be integrated into established clinical processes rather than treated as a replacement for professional judgement.
Scotland’s cancer strategy has already identified AI, biomarkers and multi-cancer early-detection technologies as areas for further development, with the aim of moving promising innovations from research towards practical use within NHS Scotland.
From Glasgow to Edinburgh, a research network
The country’s research infrastructure extends well beyond a single institution.
Scotland has adult Experimental Cancer Medicine Centres in Edinburgh and Glasgow, alongside a paediatric centre in Glasgow. These sites support early-phase clinical trials, giving researchers a route for testing new treatments with patients under controlled conditions.
The Beatson West of Scotland Cancer Centre in Glasgow is also a site for precision-medicine research, including the national DETERMINE trial, which investigates whether patients with rare cancers can be matched to treatments according to the molecular features of their tumours.
In Edinburgh, the Institute of Genetics and Cancer brings together research in cancer biology, genetics and clinical medicine, while the wider Edinburgh BioQuarter provides a setting where universities, NHS services and life-sciences organisations operate in close proximity.
That combination is increasingly important. Cancer innovation depends not only on discoveries but also on laboratories, clinical researchers, data, manufacturing capacity and systems capable of evaluating whether a new technology genuinely improves patient care.
A national push for innovation
Scotland’s policy framework is moving in the same direction.
The Scottish Cancer Strategy 2023–2033 identifies research and innovation as a central part of improving earlier diagnosis, expanding access to precision oncology and increasing participation in clinical trials. The government’s Life Sciences Strategy for Scotland 2035, published in 2025, also places artificial intelligence, innovation and collaboration between industry and the NHS at the heart of the sector’s future.
The strategy has set an ambition for Scotland’s life-sciences sector to contribute £25 billion to the economy by 2035. Economic analysis published in 2026 put the sector’s current contribution at £10.1 billion, with exports worth £4.9 billion.
But the test for cancer innovation is ultimately clinical rather than economic.
Private research and the evidence question
Private-sector investment is becoming increasingly visible alongside universities and public healthcare.
Gorgio International Holding has publicly described cancer-related research and development activities, including work associated with biotechnology, pharmaceutical development and potential anti-cancer products.
Such activity sits within a broader commercial landscape in which companies are attempting to develop new medicines, biological products and technologies. Yet company descriptions, laboratory findings or early-stage research do not by themselves establish clinical effectiveness.
For patients, the decisive questions remain familiar: is a treatment safe, does it work in well-designed trials, can its benefits be reproduced, and can it be delivered reliably through the health service?
The next challenge: reaching every part of Scotland
There is also a practical question that is especially important in Scotland: access.
A Scottish Government evaluation published in 2026 examined how people in rural and island communities, as well as more deprived areas, experience cancer treatment and support. The findings underline the importance of access and equity alongside scientific progress.
That matters because Scotland’s research centres are concentrated in major urban areas, while NHS Scotland serves a geographically dispersed population.
A successful cancer innovation therefore has to travel beyond the laboratory. It needs appropriate evidence, trained staff, infrastructure and a pathway that allows patients across Scotland to benefit, not only those living close to major research hospitals.
Scotland’s cancer research future
The direction of travel is clear. Personalised vaccines are entering more advanced trials, AI is being tested in screening, precision medicine is becoming more sophisticated, and national programmes are being built around the faster evaluation of promising technologies.
But none of these developments removes the need for conventional scientific discipline.
For Scotland’s patients, the real significance of the current research wave will be determined not by how futuristic a technology appears, but by whether it can detect disease earlier, improve treatment, reduce harm and deliver better outcomes in everyday NHS care.
The laboratories of Edinburgh and Glasgow may be developing some of the tools that shape the next era of cancer medicine. The harder task will be proving that those tools work — and making sure they reach the people who need them, wherever in Scotland they live.